Pharmacogenetic Perspective for Optimal Gout Management

Pharmacogenetics (PGx) is an emerging field of pharmacology focusing on how gene variations affect the patient’s response to treatment. a promising tool optimize selection and dosing medications, including urate-lowering therapies (ULTs) among patients with gout. The global prevalence gout rising, it disproportionately affects specific racial groups individuals select socioeconomic status. Genetic experimental findings have provided evidence that genetic polymorphisms associated serum urate pathology are also pharmacogenetic interest. Patients present several comorbidities, warranting use acute long-term medications increase their pill burden risk adverse drug events. Implementing PGx testing can identify who more or less likely benefit from given treatment, improve medication adherence, reduce burden. purpose this non-systematic review was evaluate contemporary for in management, especially treatment modalities could impact safety efficacy. Strong suggests carrying HLA-B*58:01 allele at higher serious life-threatening skin reactions when taking allopurinol. Additionally, disparities frequency warrant screening high-risk populations, specifically some Asian subgroups African Americans. Individuals G6PD-deficient develop hemolytic anemia methemoglobinemia pegloticase probenecid use. active form drug-metabolizing CYP2C9 NSAID-related upper gastrointestinal (GI) bleeding. Emerging clinically significant drug-gene pairs various growing. Genes found modulate allopurinol include AOX, ABCG2, SLC22A12. Meanwhile, UGT1A1 appears Febuxostat. While may toxicity benzbromarone, SLC22A12 ABCB1 were both benzbromarone probenecid. genes CYP2D6, ABCB1, cluster (rs6916345 G>A), SEPHS1 recently reported efficacy colchicine. Finally, HCG22 IL1RN linked corticosteroid anakinra, respectively. This examines synthesizes most current level using maximize pharmacotherapy.